CN115634275A - Traditional Chinese medicine preparation for treating liver cancer liver stagnation and spleen deficiency stasis toxin syndrome - Google Patents
Traditional Chinese medicine preparation for treating liver cancer liver stagnation and spleen deficiency stasis toxin syndrome Download PDFInfo
- Publication number
- CN115634275A CN115634275A CN202211515133.3A CN202211515133A CN115634275A CN 115634275 A CN115634275 A CN 115634275A CN 202211515133 A CN202211515133 A CN 202211515133A CN 115634275 A CN115634275 A CN 115634275A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- medicine preparation
- stasis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine preparation for treating liver-cancer liver-stagnation spleen-deficiency toxin-stasis syndrome, which comprises, by weight, 28-32 parts of codonopsis pilosula, 44-46 parts of astragalus membranaceus, 28-32 parts of fried bighead atractylodes rhizome, 28-32 parts of fried Chinese yam, 14-16 parts of poria cocos, 14-32 parts of curcuma zedoary, 9-11 parts of curcuma longa, 28-32 parts of sculellaria barbata, 28-32 parts of oldenlandia diffusa, 14-32 parts of radix bupleuri, 11-13 parts of dried orange peel, 23-25 parts of white paeony root, 28-32 parts of turtle shell, 14-16 parts of lucid ganoderma, 11-33 parts of radix curcumae, 14-16 parts of raw hawthorn, 2-4 parts of centipede and 9-11 parts of liquorice. The invention has the effects of reducing toxicity, improving the quality of life score of patients, relieving symptoms of hypochondriac pain, anorexia, emaciation, hypodynamia, abdominal distension and the like, can improve the quality of life of the patients, and has the synergistic anticancer effect.
Description
Technical Field
The invention relates to the field of medicines, in particular to a traditional Chinese medicine preparation for treating liver cancer liver stagnation and spleen deficiency toxin stasis.
Background
Liver cancer is a common malignant tumor, and most liver cancer patients in China are caused by viral hepatitis B. The process of cirrhosis of patients infected by hepatitis B virus is accelerated, which causes abnormal change of cancer cells in vivo, influences physiological functions of liver cells, and finally causes canceration. At present, surgical resection is the first-choice treatment method, and because the initial symptoms of liver cancer patients are hidden and the disease condition is rapidly developed, the patients often enter the middle and late stages during treatment, and the number of cases capable of being treated by surgery is only 15% -20%, so the overall survival rate of liver cancer is still low relative to 5 years.
The primary liver cancer is a common malignant tumor, has the clinical characteristics of latent morbidity, high recurrence rate, high lethality rate and the like, most patients are diagnosed with middle and late stage, the best time of the operation is missed, the prognosis is poor, the treatment of the late stage liver cancer patients is mainly comprehensive treatment, and the Chinese and western medicine treatment method plays a certain role in the late stage liver cancer. As early as in the age of Yizhou, the oracle has the disease name of tumor, the cancer starts to be used in the self-evident era, and the symptoms of liver cancer are found in diseases such as liver accumulation, hypochondriac pain, jaundice, tympanites, accumulation and the like. The basic pathogenesis of liver cancer is deficiency, dampness, stasis and toxicity, and liver depression and spleen deficiency and stasis and toxicity are the leading factors of liver cancer onset throughout the whole process. Traditional Chinese medicine has made great progress in clinical and experimental research of liver cancer.
Disclosure of Invention
In order to solve the technical problems in the background technology, the invention provides a traditional Chinese medicine preparation for treating liver cancer liver stagnation and spleen deficiency stasis toxin syndrome, which has the effects of reducing toxicity and enhancing effect, improving the quality of life score of a patient, relieving symptoms such as hypochondriac pain, anorexia, emaciation, hypodynamia and abdominal distension, can improve the quality of life of the patient, and has a synergistic anticancer effect.
The technical solution of the invention is as follows: the invention relates to a traditional Chinese medicine preparation for treating liver cancer liver stagnation and spleen deficiency stasis toxin syndrome, which is characterized in that: the traditional Chinese medicine preparation for treating liver cancer liver depression and spleen deficiency toxin stasis syndrome comprises, by weight, 28-32 parts of codonopsis pilosula, 44-46 parts of astragalus membranaceus, 28-32 parts of fried bighead atractylodes rhizome, 28-32 parts of fried Chinese yam, 14-16 parts of poria cocos, 14-32 parts of curcuma zedoary, 9-11 parts of turmeric, 28-32 parts of sculellaria barbata, 28-32 parts of oldenlandia diffusa, 14-32 parts of radix bupleuri, 11-13 parts of dried orange peel, 23-25 parts of white paeony root, 28-32 parts of turtle shell, 14-16 parts of lucid ganoderma, 11-33 parts of radix curcumae, 14-16 parts of raw hawthorn, 2-4 parts of centipede and 9-11 parts of liquorice.
Furthermore, the traditional Chinese medicine preparation for treating liver cancer liver stagnation and spleen deficiency toxin stasis syndrome also comprises, by weight, 9-11 parts of endothelium corneum gigeriae galli, 19-21 parts of malt, 9-11 parts of medicated leaven, 9-11 parts of rhizoma corydalis, 14-16 parts of fingered citron and 14-16 parts of trogopterus dung.
Furthermore, the traditional Chinese medicine preparation for treating liver cancer liver stagnation spleen deficiency toxin stasis syndrome also comprises 14-16 parts of ginseng and 14-16 parts of suberect spatholobus stem by weight percentage.
Further, the traditional Chinese medicine preparation for treating liver cancer liver stagnation and spleen deficiency stasis toxin syndrome also comprises 14-16 parts by weight of radish seed and 14-16 parts by weight of magnolia officinalis.
Furthermore, the traditional Chinese medicine preparation for treating liver cancer liver stagnation and spleen deficiency stasis toxin syndrome also comprises 28-32 parts of oriental wormwood and 14-16 parts of cape jasmine fruit by weight percentage.
Furthermore, the traditional Chinese medicine preparation for treating liver cancer liver stagnation spleen deficiency toxin stasis syndrome also comprises 28-32 parts of tortoise plastron and 9-11 parts of rhizoma sparganii according to weight percentage.
Furthermore, the traditional Chinese medicine preparation for treating liver cancer liver stagnation spleen deficiency toxin stasis syndrome also comprises 9-11 parts of rhizoma cyperi and 9-11 parts of fingered citron by weight percentage.
Furthermore, the traditional Chinese medicine preparation for treating liver cancer liver stagnation and spleen deficiency toxin stasis syndrome also comprises 9-11 parts of fructus cannabis, 9-11 parts of bunge cherry seed, 9-11 parts of rhubarb and 9-11 parts of mirabilite by weight percentage.
Further, the traditional Chinese medicine preparation for treating liver cancer liver stagnation and spleen deficiency toxin stasis comprises, by weight, 14-16 parts of dark plum, 14-16 parts of nutmeg and 14-16 parts of white hyacinth bean.
Further, the traditional Chinese medicine preparation for treating liver cancer liver stagnation and spleen deficiency stasis toxin syndrome also comprises 14-16 parts of areca peel, 28-32 parts of polyporus umbellatus and 28-32 parts of rhizoma alismatis in percentage by weight.
The traditional Chinese medicine considers that liver diseases are caused by long-term deficiency of qi and blood of viscera, spleen deficiency and dampness accumulation, phlegm coagulation and blood stasis; invasion of pathogenic toxin, blood coagulation and toxin coagulation; internal injury due to seven emotions, dysfunction of the spleen in transport and transformation, and liver regulation, which leads to stagnation of qi and blood and accumulation of phlegm-fire. Spleen deficiency is the root cause of liver cancer. Qi deficiency and blood stasis occur along with the development of spleen deficiency; with the development of liver depression and qi stagnation, qi stagnation and blood stasis appear; meanwhile, "toxin" such as viral hepatitis, aflatoxin, drinking water pollution and the like can enter in the deficiency, and toxin stasis is combined to cause the disease. In the early stage, healthy qi begins to be deficient and toxic stasis is gradually formed, and no obvious symptoms are usually found at this time. In the middle stage, along with the development of the disease, the lump (toxic stasis) as a pathological product is further transformed into a cause of disease and acts on the body, so that the deficiency of vital qi is aggravated, and the toxic stasis is further developed, thereby forming a vicious circle. In the late stage of the disease, the stagnant toxin is strong, the vital qi is deficient and weak, namely, the vital qi is deficient and the pathogenic factors are strong, the tumor is progressively enlarged, the jaundice, the ascites and the cachexia appear, or the distant metastasis exists, and the diet and the daily life are seriously affected. The deficiency and blood stasis toxicity coexist all the time, are cause and effect with each other, influence each other and have a vicious circle, and run through the whole course of liver cancer, and the deficiency and blood stasis toxicity is the basic etiology and pathogenesis of the liver cancer.
Therefore, the treatment principle of the invention is to take the root cause and symptoms into consideration, and the invention has the dual purposes of strengthening the body resistance and eliminating pathogenic factors, and is mainly used for strengthening the body resistance and conditioning. In treatment, starting from the spleen and kidney, the treatment methods of invigorating spleen and regulating qi, tonifying liver and kidney, removing blood stasis and softening hard masses, and resolving masses and detoxifying are used as major methods, and are assisted by regulating emotion. The traditional Chinese medicine for treating liver cancer has unique advantages in the aspects of reducing toxicity, improving efficacy, improving life quality, improving symptoms and reducing toxic and side effects. The invention relates to an empirical prescription taking strengthening spleen and replenishing qi, soothing liver and softening hard mass, and detoxifying and resolving hard mass as a treatment rule, which comprises codonopsis pilosula, astragalus, bighead atractylodes rhizome, radix bupleuri, rhizoma sparganii, ligusticum wallichii, turmeric, centipede, barbed skullcap herb, oldenlandia diffusa and other traditional Chinese medicines. Strengthening body resistance and consolidating constitution, i.e. regulating body resistance through drugs, i.e. enhancing immunity in modern medicineForce. Research shows that astragalus polysaccharide which is the main component of astragalus has the function of immunoregulation and can participate in the regulation of immune response of organisms; the polysaccharide compound in the codonopsis pilosula also has the activity of enhancing the immunologic function; the herba Scutellariae Barbatae ethanol extract, water extract and chloroform extract all have certain anti-tumor effect, and diterpene compound Scutebabalactone VN can reduce CDC25A and AURKA gene expression, and block NF-kB pathway to inhibit tumor cell growth. Herba Hedyotidis Diffusae containing anthraquinone, flavonoid, terpene and steroid compounds with anticancer activity [21] 。
The research result shows that in the aspect of liver function, the body resistance strengthening and anticancer formula and the control group have no obvious difference before treatment, and the ALT level after treatment of the body resistance strengthening and anticancer formula is obviously reduced compared with that before treatment, which indicates that the body resistance strengthening and anticancer formula has the functions of reducing transaminase and protecting liver function; however, in other indexes, the PTA, TBIL, WBC, HGB and AFP levels are not obviously different between the two groups before and after treatment. In the aspect of traditional Chinese medicine symptoms, before and after treatment of the body resistance strengthening and anticancer formula, the statistical difference exists in the aspects of improvement of costalgia, anorexia, emaciation, hypodynamia and abdominal distension symptoms, and the other traditional Chinese medicine symptoms do not have obvious difference. The scores of the pre-treatment and post-treatment living quality (EQ-5D) of the body resistance strengthening and anticancer formula group have statistical significance, while the score of the post-treatment living quality of the control group has no obvious difference with the score before treatment.
After the treatment of the body resistance strengthening and anticancer formula group, the traditional Chinese medicine syndrome score is obviously higher than that before the treatment and after the control group treatment, and the life quality score is also obviously better than that before the treatment. The results show that the traditional Chinese medicine syndrome and the quality of life of the primary liver cancer patient are scored by combining the body resistance strengthening and anticancer prescription with western medicine comprehensive treatment, the side effect of the western medicine treatment on the liver function is also obviously improved, and the liver function index effect of the western medicine comprehensive treatment of the patient is improved.
In conclusion, the body resistance strengthening and anticancer prescription has obvious curative effect on patients with liver cancer, liver depression, spleen deficiency and toxin stasis syndrome, has the effects of reducing toxicity, improving the effect, improving the quality of life score of the patients, relieving symptoms such as hypochondriac pain, anorexia, emaciation, hypodynamia and abdominal distension, can improve the quality of life of the patients, and has a synergistic anticancer effect.
The invention adopts a real world research method to select 68 patients with primary liver cancer as research objects, and the patients are divided into a control group (38 cases) and a body resistance strengthening and anti-cancer formula group (30 cases) according to different treatment schemes. Comparing the change of liver function glutamic pyruvic transaminase (ALT), total bilirubin (Tbil), prothrombin Time (PT), serum leukocyte (WBC), hemoglobin (HGB), alpha-fetoprotein (AFP), chinese medicine evidence and quality of life (EQ-5D) score before and after treatment of the control group and the body-strengthening anticancer group. As a result: the ALT level of the body resistance strengthening and anticancer prescription is obviously reduced compared with that before treatment, which indicates that the body resistance strengthening and anticancer prescription has the function of protecting liver function; compared with the levels of PTA, TBIL, WBC, HGB and AFP before and after treatment, the difference has no statistical significance (P is more than 0.05). In the aspect of traditional Chinese medicine symptoms, before and after treatment of the body resistance strengthening and anticancer formula, the differences have statistical significance (P is less than 0.05) in the aspects of improvement of costalgia, anorexia, emaciation, hypodynamia and abdominal distension symptoms. The score of the vital quality before and after treatment (EQ-5D) of the body resistance strengthening and anticancer formula group is statistically different (P is less than 0.05), and the score of the vital quality after treatment of the control group is compared with that before treatment, and the difference has no statistical significance (P is more than 0.05). And (4) conclusion: the body resistance strengthening and anticancer prescription has obvious curative effect on patients with liver cancer, liver depression, spleen deficiency and toxin stasis syndrome, has the effects of reducing toxicity, improving the efficacy, improving the quality of life score, relieving symptoms such as hypochondriac pain, anorexia, emaciation, hypodynamia and abdominal distension, can improve the quality of life of the patients, and has a synergistic anticancer effect.
Detailed Description
The present invention will be described in further detail with reference to specific examples below:
the ingredients of the first specific embodiment of the invention include, by weight, 30 parts of codonopsis pilosula, 45 parts of astragalus membranaceus, 30 parts of fried bighead atractylodes rhizome, 30 parts of fried Chinese yam, 15 parts of poria cocos, 15 parts of curcuma zedoary, 10 parts of curcuma longa, 30 parts of sculellaria barbata, 30 parts of oldenlandia diffusa, 15 parts of radix bupleuri, 12 parts of pericarpium citri reticulatae, 24 parts of radix paeoniae alba, 30 parts of turtle shell, 15 parts of ganoderma lucidum, 12 parts of radix curcumae, 15 parts of raw hawthorn, 3 parts of centipede and 10 parts of liquorice.
The second specific embodiment of the invention comprises, by weight, 30 parts of codonopsis pilosula, 45 parts of astragalus membranaceus, 30 parts of fried bighead atractylodes rhizome, 30 parts of fried Chinese yam, 15 parts of poria cocos, 15 parts of curcuma zedoary, 10 parts of curcuma longa, 30 parts of sculellaria barbata, 30 parts of oldenlandia diffusa, 15 parts of radix bupleuri, 12 parts of pericarpium citri reticulatae, 24 parts of radix paeoniae alba, 30 parts of turtle shell, 15 parts of ganoderma lucidum, 12 parts of radix curcumae, 15 parts of raw hawthorn, 3 parts of centipede, 10 parts of liquorice, 10 parts of endothelium corneum gigeriae galli, 20 parts of malt and 10 parts of medicated leaven.
The third concrete embodiment of the invention comprises, by weight, 30 parts of codonopsis pilosula, 45 parts of astragalus membranaceus, 30 parts of fried bighead atractylodes rhizome, 30 parts of fried Chinese yam, 15 parts of poria cocos, 15 parts of curcuma zedoary, 10 parts of curcuma longa, 30 parts of sculellaria barbata, 30 parts of oldenlandia diffusa, 15 parts of radix bupleuri, 12 parts of pericarpium citri reticulatae, 24 parts of radix paeoniae alba, 30 parts of turtle shell, 15 parts of ganoderma lucidum, 12 parts of radix curcumae, 15 parts of raw hawthorn, 3 parts of centipede, 10 parts of liquorice, 10 parts of rhizoma corydalis, 15 parts of fingered citron and 15 parts of trogopterus dung.
The fourth specific embodiment of the invention comprises 30 portions of radix codonopsitis, 45 portions of radix astragali, 30 portions of fried rhizoma atractylodis macrocephalae, 30 portions of fried yam, 15 portions of tuckahoe, 15 portions of rhizoma zedoariae, 10 portions of turmeric, 30 portions of sculellaria barbata, 30 portions of oldenlandia diffusa, 15 portions of radix bupleuri, 12 portions of dried orange peel, 24 portions of white peony root, 30 portions of turtle shell, 15 portions of ganoderma lucidum, 12 portions of radix curcumae, 15 portions of raw hawthorn, 3 portions of centipede, 10 portions of liquorice, 15 portions of ginseng and 15 portions of caulis spatholobi.
The five specific embodiments of the invention comprise 30 parts of radix codonopsitis, 45 parts of radix astragali, 30 parts of fried rhizoma atractylodis macrocephalae, 30 parts of fried Chinese yam, 15 parts of tuckahoe, 15 parts of rhizoma zedoariae, 10 parts of turmeric, 30 parts of sculellaria barbata, 30 parts of oldenlandia diffusa, 15 parts of radix bupleuri, 12 parts of dried orange peel, 24 parts of white peony root, 30 parts of turtle shell, 15 parts of ganoderma lucidum, 12 parts of radix curcumae, 15 parts of raw hawthorn, 3 parts of centipede, 10 parts of liquorice, 15 parts of semen raphani and 15 parts of magnolia officinalis.
According to a sixth specific embodiment of the invention, the ingredients comprise, by weight, 30 parts of codonopsis pilosula, 45 parts of astragalus membranaceus, 30 parts of fried bighead atractylodes rhizome, 30 parts of fried Chinese yam, 15 parts of poria cocos, 15 parts of curcuma zedoary, 10 parts of curcuma longa, 30 parts of sculellaria barbata, 30 parts of oldenlandia diffusa, 15 parts of radix bupleuri, 12 parts of pericarpium citri reticulatae, 24 parts of radix paeoniae alba, 30 parts of turtle shell, 15 parts of ganoderma lucidum, 22 parts of radix curcumae, 15 parts of raw hawthorn, 3 parts of centipede, 10 parts of liquorice, 30 parts of oriental wormwood and 15 parts of cape jasmine.
The seventh specific embodiment of the invention comprises, by weight, 30 parts of codonopsis pilosula, 45 parts of astragalus membranaceus, 30 parts of fried bighead atractylodes rhizome, 30 parts of fried Chinese yam, 15 parts of poria cocos, 30 parts of curcuma zedoary, 10 parts of curcuma longa, 30 parts of sculellaria barbata, 30 parts of oldenlandia diffusa, 15 parts of radix bupleuri, 12 parts of pericarpium citri reticulatae, 24 parts of radix paeoniae alba, 30 parts of turtle shell, 15 parts of ganoderma lucidum, 12 parts of radix curcumae, 15 parts of raw hawthorn, 3 parts of centipede, 10 parts of liquorice, 30 parts of tortoise plastron and 10 parts of rhizoma sparganii.
The eight specific embodiments of the invention comprise, by weight, 30 parts of codonopsis pilosula, 45 parts of astragalus membranaceus, 30 parts of fried bighead atractylodes rhizome, 30 parts of fried Chinese yam, 15 parts of poria cocos, 15 parts of curcuma zedoary, 10 parts of curcuma longa, 30 parts of sculellaria barbata, 30 parts of oldenlandia diffusa, 30 parts of radix bupleuri, 12 parts of pericarpium citri reticulatae, 24 parts of radix paeoniae alba, 30 parts of turtle shell, 15 parts of ganoderma lucidum, 22 parts of radix curcumae, 15 parts of raw hawthorn, 3 parts of centipede, 10 parts of liquorice, 10 parts of rhizoma cyperi and 10 parts of fingered citron.
The composition of the ninth embodiment of the invention comprises 30 parts by weight of radix codonopsitis, 45 parts by weight of radix astragali, 30 parts by weight of rhizoma atractylodis macrocephalae, 30 parts by weight of rhizoma dioscoreae preparata, 15 parts by weight of poria cocos, 15 parts by weight of rhizoma zedoariae, 10 parts by weight of curcuma longa, 30 parts by weight of sculellaria barbata, 30 parts by weight of oldenlandia diffusa, 15 parts by weight of radix bupleuri, 12 parts by weight of dried orange peel, 24 parts by weight of white peony root, 30 parts by weight of turtle shell, 15 parts by weight of ganoderma lucidum, 12 parts by weight of radix curcumae, 15 parts by weight of raw hawthorn, 3 parts by weight of centipede, 10 parts by weight of liquorice, 10 parts by weight of fructus cannabis, 10 parts by weight of bunge cherry seed, 10 parts by weight of rhubarb and 9 parts by weight of mirabilite.
The ten components of the specific embodiment of the invention comprise 30 parts of radix codonopsitis, 45 parts of astragalus root, 30 parts of fried rhizoma atractylodis macrocephalae, 30 parts of fried Chinese yam, 15 parts of tuckahoe, 15 parts of rhizoma zedoariae, 10 parts of turmeric, 30 parts of sculellaria barbata, 30 parts of oldenlandia diffusa, 15 parts of radix bupleuri, 12 parts of dried orange peel, 24 parts of white peony root, 30 parts of turtle shell, 15 parts of ganoderma lucidum, 12 parts of radix curcumae, 15 parts of raw hawthorn, 3 parts of centipede, 10 parts of liquorice, 15 parts of dark plum, 15 parts of nutmeg and 15 parts of white hyacinth bean by weight.
The eleven specific embodiment of the invention comprises, by weight, 30 parts of codonopsis pilosula, 45 parts of astragalus mongholicus, 30 parts of fried bighead atractylodes rhizome, 30 parts of fried Chinese yam, 15 parts of poria cocos, 15 parts of curcuma zedoary, 10 parts of turmeric, 30 parts of sculellaria barbata, 30 parts of oldenlandia diffusa, 15 parts of radix bupleuri, 12 parts of pericarpium citri reticulatae, 24 parts of radix paeoniae alba, 30 parts of turtle shell, 15 parts of ganoderma lucidum, 12 parts of radix curcumae, 15 parts of raw hawthorn, 3 parts of centipede, 10 parts of liquorice, 15 parts of pericarpium arecae, 30 parts of polyporus umbellatus and 30 parts of rhizoma alismatis.
The twelve components of the specific embodiment of the invention comprise 30 parts of codonopsis pilosula, 30 parts of fried bighead atractylodes rhizome, 30 parts of fried Chinese yam, 15 parts of poria cocos, 15 parts of curcuma zedoary, 10 parts of turmeric, 30 parts of sculellaria barbata, 30 parts of oldenlandia diffusa, 15 parts of radix bupleuri, 12 parts of dried orange peel, 24 parts of white paeony root, 30 parts of turtle shell, 15 parts of lucid ganoderma, 12 parts of radix curcumae, 15 parts of raw hawthorn, 3 parts of centipede, 10 parts of liquorice, 15 parts of root of straight ladybell, 15 parts of radix ophiopogonis and 10 parts of rhizoma anemarrhenae in percentage by weight.
The preparation method of one specific embodiment of the invention is a decoction piece preparation method: the method comprises the following steps:
1) Before decocting, taking 30 parts of codonopsis pilosula, 45 parts of astragalus, 30 parts of fried bighead atractylodes rhizome, 30 parts of fried Chinese yam, 15 parts of poria cocos, 15 parts of curcuma zedoary, 10 parts of turmeric, 30 parts of sculellaria barbata, 30 parts of oldenlandia diffusa, 15 parts of radix bupleuri, 12 parts of dried orange peel, 24 parts of white paeony root, 30 parts of turtle shell, 15 parts of lucid ganoderma, 12 parts of radix curcumae, 15 parts of raw hawthorn, 3 parts of centipede and 10 parts of liquorice;
2) Crushing carapax Trionycis, decocting with slow fire for half an hour, soaking the rest Chinese medicinal decoction pieces in cold water and clear water until the decoction pieces are submerged for about 2cm, soaking for 30 min, decocting carapax Trionycis for 30 min, and decocting the rest materials in casserole;
3) Decocting twice, wherein during the first decoction, big fire (strong fire) is used before boiling, and small fire (slow fire) is used after boiling to keep the micro-boiling state, boiling for about 30 minutes, and filtering the liquid medicine; during the second decoction, water is added to submerge the decoction pieces by about 2cm, the big fire is used before boiling, the slight boiling state is kept by small fire after boiling, the decoction is boiled for 30 minutes, and the liquid medicine is filtered.
The first decoction and the second decoction are mixed evenly and then taken twice, wherein the first decoction and the second decoction are taken once 1 hour before breakfast and supper, and each time is 200ml for adults.
The following are comparative experimental data of the present invention to further illustrate the efficacy of the present invention.
68 primary liver cancer patients diagnosed in Shaanxi province tumor hospital in 2021 to 2022 in 7 months are selected as study objects, and divided into two groups according to the will of the patients, 30 patients in a body resistance strengthening and anticancer group and 38 patients in a control group. The prescription group for strengthening body resistance and resisting cancer: 25 men and 5 women; mean age (59.93 ± 10.41) years. Control group: 30 men and 8 women; mean age (53.68 ± 9.23) years. The disease case inclusion standard accords with the diagnosis standard of primary liver cancer in the primary liver cancer diagnosis and treatment standard, and is confirmed by the combination of imaging examination and pathological examination and clinical manifestations; there is a history of viral hepatitis B; when the survival patient is admitted into hospital, the liver function index, serum WBC and AFP data are complete after 3 months of treatment; age 34-79 years; the traditional Chinese medicine composition meets the traditional Chinese medicine diagnosis standards of 'mass', 'accumulation' and 'liver stagnation', the main symptoms are hypochondriac pain and abdominal distension, the secondary symptoms are emaciation and hypodynamia, dry mouth and bitter taste, inappetence, vexation and irritability, and the tongue pulse symptoms are red tongue with thin fur and wiry pulse; the study was approved by the hospital medical ethics committee, ethics approval No. (shang ma medical ceremony examination (2021) No. 59). Exclusion criteria patients who failed to adhere to treatment; patients with severe adverse events or severe adverse reactions; allergic to the study drug; patients who use other Chinese and western medicines prohibited by the scheme; patients with inadequate clinical data. The general data of two groups of patients are compared, and the difference is not statistically significant (P is more than 0.05) and is comparable.
1.2 methods of treatment
1.2.1 control group: the western medicine comprehensive treatment and the conventional comprehensive scheme are given. The immune checkpoint inhibitor is combined with TKI molecular targeted drugs, local TACE, ablation and the like are combined, and antiviral treatment, liver protection and acid inhibition, nutritional support and other symptomatic treatment are simultaneously given.
1.2.2 group of anti-cancer prescription: the treatment based on the control group is carried out according to the syndrome differentiation of the traditional Chinese medicine, and is added or subtracted according to the syndrome on the basis of the formula for strengthening the body resistance and resisting the cancer. The formula for strengthening body resistance and resisting cancer is an empirical formula which is added or subtracted based on syndrome differentiation on the basis of meridian formula Sijunzi decoction and radix bupleuri liver-soothing powder, and comprises 30g of codonopsis pilosula, 45g of astragalus membranaceus, 30g of fried bighead atractylodes rhizome, 30g of fried Chinese yam, 15g of poria cocos, 15g of curcuma zedoary, 10g of curcuma longa, 30g of sculellaria barbata, 30g of oldenlandia diffusa, 15g of radix bupleuri, 12g of pericarpium citri reticulatae, 24g of radix paeoniae alba, 30g of turtle shell, 15g of lucid ganoderma, 12g of radix curcumae, 15g of raw hawthorn, 3g of centipede, 10g of liquorice and the like. The dosage of the traditional Chinese medicine is increased or decreased according to the symptoms of the individual patients during clinical dialectical treatment, and the dosage of the traditional Chinese medicine is determined according to the degree of the patients. Rhizoma corydalis 10g, fructus Citri Sarcodactylis 15g, and Oletum Trogopterori 15g can be added for patients with hypochondriac pain; for patients with obvious anorexia, 10g of endothelium corneum Gigeriae Galli and 20g of fructus Hordei Germinatus Massa Medicata Fermentata are added; for patients with obvious asthenia, 15g of ginseng and 15g of suberect spatholobus stem are added into the codonopsis pilosula; 15g of radish seed and 15g of magnolia bark are added for patients with obvious abdominal distension; 30g of oriental wormwood, 10g of radix curcumae and 15g of cape jasmine for patients with jaundice; for patients with yin deficiency and fire excess, radix astragali is removed, and 15g of radix Adenophorae, 15g of radix Ophiopogonis and 10g of rhizoma anemarrhenae are added; 30g of tortoise plastron, 10g of rhizoma sparganii, 15g of curcuma zedoary, 15g of radix bupleuri, 10g of rhizoma cyperi, 10g of radix curcumae and 10g of fingered citron are added for patients with liver and spleen swelling discomfort and patients with chest distress and good tai; adding 10g of fructus cannabis, 10g of bunge cherry seed, 10g of rheum officinale and 9g of mirabilite into dried excrement; for patients with diarrhea and loose stool, add smoked plum 15g, nutmeg 15g, white hyacinth bean 15g; removing radix Paeoniae alba for patients with long-term heat accumulation of blood stasis, and adding radix Paeoniae Rubra 15g, cortex moutan 15g, and fructus Gardeniae 15g; 15g of pericarpium arecae and 30g of polyporus umbellatus and 30g of rhizoma alismatis for patients with obvious ascites. The decoction is prepared into decoction pieces, 1 dose is taken every day, the decoction is decocted with water for 2 times, 200ml is taken every time, the decoction is taken in the morning and at night, and 1 month is a treatment course.
1.3 observation indexes tumor markers: the levels of alpha-fetoprotein (AFP) were measured before and after treatment in both groups of patients. The prothrombin activity (PTA), total Bilirubin (TBIL), alanine Aminotransferase (ALT), white Blood Cells (WBC), and Hemoglobin (HGB) were measured before and after treatment in two groups of patients. Scoring of traditional Chinese medicine syndromes: according to the standard of curative effect of diagnosis of traditional Chinese medicine diseases, patients are scored according to symptoms of no (0 point), mild (1 point), moderate (2 points) and severe (3 points) such as hypochondriac pain, anorexia, loose stool, dry stool, emaciation, mental fatigue and hypodynamia, abdominal distension, chest distress and good respiration, anorexia, abdominal mass, inappetence, insomnia, vexation and irritability. Quality of life scoring: the Quality of Life Questionnaire (Quality of Life questinaire, QLQ) -C30 scale issued by European cancer research and treatment organization is adopted for scoring, 5 fields including body function, role function, cognitive function, emotional function and social function are included, each field is divided into 0-100 points, and the higher the score is, the higher the Quality of Life is.
1.4 statistical methods
All data were processed using SPSS 22.0 statistical software. The measurement data conforming to the positive-Taiji distribution is expressed by x +/-s, t test is adopted for comparison between two groups, variance analysis is adopted between multiple groups, measurement data with non-normal distribution is expressed by M (Interquartile range, IQR (interquartile range)), rank sum test is adopted for comparison between groups, and P <0.05 has statistical significance for difference.
2 results
2.1 comparison of laboratory indices for two groups of patients before and after treatment is shown in Table 1. Before treatment, the PTA, TBIL and ALT levels of the body resistance strengthening and anticancer formula group have no obvious difference with the control group (P is more than 0.05). The ALT level of the body resistance strengthening and anticancer prescription group is obviously reduced compared with that before treatment, which shows that the body resistance strengthening and anticancer prescription group has the function of liver function protection, while the ALT level of the control group has no statistical difference before and after treatment; there was no significant difference in PTA, TBIL levels between the two groups before and after treatment (P > 0.05). Before treatment, the WBC, HGB and AFP levels of the healthy anticancer prescription group have no obvious difference with the control group (P is more than 0.05). The WBC, HGB, AFP levels were not significantly different from treatment in both groups (P > 0.05).
TABLE 1 comparison of hepatic function index changes before and after treatment [ M (IQR) ]
Note: * P <0.05,. P <0.01.
2.3 quality of life (EQ-5D) scores of two groups of patients before treatment, the quality of life scores of the body resistance strengthening and anticancer formula group are compared with those of the control group, and the difference is not statistically significant (P is more than 0.05). The differences of the life quality scores of the body resistance strengthening and anticancer formula after treatment are statistically significant (P is less than 0.05) compared with the life quality scores of the control formula before treatment, while the differences of the life quality scores of the control formula after treatment are not statistically significant (P is more than 0.05) compared with the life quality scores of the control formula before treatment, see table 2.
TABLE 2 two groups of patients' quality of life score comparison (score)
Note: * P <0.05, P <0.01.
2.4 the Chinese medicine syndrome scores of two groups of patients are shown in Table 3. The statistic analysis of the syndrome grade shows that the anti-cancer prescription group and the control group can strengthen the body resistance: the control group has different degrees of costalgia, 13.3 percent of the body resistance strengthening and anticancer square group has no symptoms, 53.3 percent of mild patients, and the two groups have statistical difference (P is less than 0.05). 16.7% of patients in the strengthening and anticancer prescription group have chest distress and taiming symptoms, 16.7% of patients have mild symptoms, moderate symptoms are 23.3% and severe symptoms are 13.3%, 34.2% of patients in the control group have mild symptoms and 65.8% of patients have moderate symptoms, and the two groups have statistical difference (P is less than 0.05). The patients with anorexia have 26.7% of asymptomatic patients and 23.3% of mild patients in the anti-cancer group, while the control group has different degrees of anorexia symptoms, wherein the mild patients have 65.8% of symptoms, the moderate patients have 26.3% of symptoms and the severe patients have 7.9% of symptoms, and the two groups have statistical difference (P is less than 0.05). The patients in the control group all have symptoms of listlessness and hypodynamia, while 50% of the patients in the anti-cancer formula group have no obvious symptoms, 23.3% of the patients have mild symptoms, and P is less than 0.05. The patients in the control group all have abdominal distension with different degrees, while 26.7 percent of the patients in the prescription group with the function of strengthening the body resistance and resisting cancer have no obvious symptoms, and 30 percent of the patients are all mild. Emaciation, the patients in the control group all have different degrees of emaciation, 63.3 percent of the patients in the body resistance strengthening and anti-cancer formula group have no emaciation symptoms, 33.3 percent of the patients are mild, and the rest traditional Chinese medicine syndromes have no obvious difference.
TABLE 3 comparison (score) of the Chinese medical syndrome scores of the two groups of patients after treatment
Note: * P <0.05,. P <0.01.
The present disclosure and the technical contents not specifically described in the above embodiments are the same as the prior art.
The present invention is not limited to the above-described embodiments, and the present invention can be carried out with the above-described advantageous effects.
The above are only specific embodiments disclosed in the present invention, but the scope of the present invention is not limited thereto, and the scope of the present invention should be determined by the scope of the claims.
Claims (10)
1. A traditional Chinese medicine preparation for treating liver cancer stagnation and spleen deficiency syndrome of toxin stasis is characterized in that: the traditional Chinese medicine preparation for treating liver cancer liver depression and spleen deficiency toxin stasis syndrome comprises, by weight, 28-32 parts of codonopsis pilosula, 44-46 parts of astragalus membranaceus, 28-32 parts of fried bighead atractylodes rhizome, 28-32 parts of fried Chinese yam, 14-16 parts of poria cocos, 14-32 parts of curcuma zedoary, 9-11 parts of turmeric, 28-32 parts of sculellaria barbata, 28-32 parts of oldenlandia diffusa, 14-32 parts of radix bupleuri, 11-13 parts of dried orange peel, 23-25 parts of white paeony root, 28-32 parts of turtle shell, 14-16 parts of lucid ganoderma, 11-33 parts of radix curcumae, 14-16 parts of raw hawthorn, 2-4 parts of centipede and 9-11 parts of liquorice.
2. The traditional Chinese medicine preparation for treating liver cancer, liver stagnation, spleen deficiency and toxin stasis as recited in claim 1, wherein: the traditional Chinese medicine preparation for treating liver cancer liver stagnation and spleen deficiency stasis toxin syndrome further comprises, by weight, 9-11 parts of endothelium corneum gigeriae galli, 19-21 parts of malt, 9-11 parts of medicated leaven, 9-11 parts of rhizoma corydalis, 14-16 parts of fingered citron and 14-16 parts of trogopterus dung.
3. The traditional Chinese medicine preparation for treating liver cancer, liver stagnation, spleen deficiency and toxin stasis as recited in claim 1, wherein: the traditional Chinese medicine preparation for treating liver cancer liver stagnation and spleen deficiency stasis toxin syndrome also comprises 14-16 parts by weight of ginseng and 14-16 parts by weight of suberect spatholobus stem.
4. The traditional Chinese medicine preparation for treating liver cancer liver stagnation and spleen deficiency stasis toxin syndrome according to claim 1, which is characterized in that: the traditional Chinese medicine preparation for treating liver cancer liver stagnation and spleen deficiency stasis toxin syndrome further comprises 14-16 parts by weight of radish seed and 14-16 parts by weight of magnolia officinalis.
5. The traditional Chinese medicine preparation for treating liver cancer, liver stagnation, spleen deficiency and toxin stasis as recited in claim 1, wherein: the traditional Chinese medicine preparation for treating liver cancer liver stagnation and spleen deficiency stasis toxin syndrome further comprises 28-32 parts of oriental wormwood and 14-16 parts of cape jasmine fruit in percentage by weight.
6. The traditional Chinese medicine preparation for treating liver cancer, liver stagnation, spleen deficiency and toxin stasis as recited in claim 1, wherein: the traditional Chinese medicine preparation for treating liver cancer liver stagnation and spleen deficiency toxin stasis syndrome further comprises 28-32 parts of tortoise plastron and 9-11 parts of rhizoma sparganii in percentage by weight.
7. The traditional Chinese medicine preparation for treating liver cancer, liver stagnation, spleen deficiency and toxin stasis as recited in claim 1, wherein: the traditional Chinese medicine preparation for treating liver cancer liver stagnation and spleen deficiency toxin stasis syndrome also comprises 9-11 parts by weight of rhizoma cyperi and 9-11 parts by weight of fingered citron.
8. The traditional Chinese medicine preparation for treating liver cancer, liver stagnation, spleen deficiency and toxin stasis as recited in claim 1, wherein: the traditional Chinese medicine preparation for treating liver cancer liver stagnation and spleen deficiency stasis toxin syndrome also comprises 9-11 parts by weight of fructus cannabis, 9-11 parts by weight of bunge cherry seed, 9-11 parts by weight of rhubarb and 9-11 parts by weight of mirabilite.
9. The traditional Chinese medicine preparation for treating liver cancer liver stagnation and spleen deficiency stasis toxin syndrome according to claim 1, which is characterized in that: the traditional Chinese medicine preparation for treating liver cancer liver stagnation and spleen deficiency toxin stasis syndrome also comprises 14-16 parts of dark plum, 14-16 parts of nutmeg and 14-16 parts of white hyacinth bean by weight percentage.
10. The traditional Chinese medicine preparation for treating liver cancer, liver stagnation, spleen deficiency and toxin stasis as recited in claim 1, wherein: the traditional Chinese medicine preparation for treating liver cancer liver stagnation and spleen deficiency toxin stasis syndrome also comprises 14-16 parts of areca peel, 28-32 parts of grifola and 28-32 parts of rhizoma alismatis in percentage by weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211515133.3A CN115634275A (en) | 2022-11-30 | 2022-11-30 | Traditional Chinese medicine preparation for treating liver cancer liver stagnation and spleen deficiency stasis toxin syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211515133.3A CN115634275A (en) | 2022-11-30 | 2022-11-30 | Traditional Chinese medicine preparation for treating liver cancer liver stagnation and spleen deficiency stasis toxin syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115634275A true CN115634275A (en) | 2023-01-24 |
Family
ID=84949167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211515133.3A Pending CN115634275A (en) | 2022-11-30 | 2022-11-30 | Traditional Chinese medicine preparation for treating liver cancer liver stagnation and spleen deficiency stasis toxin syndrome |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115634275A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115300575A (en) * | 2021-05-08 | 2022-11-08 | 首都医科大学附属北京地坛医院 | A Chinese medicinal composition for treating hepatitis B-related liver cancer |
-
2022
- 2022-11-30 CN CN202211515133.3A patent/CN115634275A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115300575A (en) * | 2021-05-08 | 2022-11-08 | 首都医科大学附属北京地坛医院 | A Chinese medicinal composition for treating hepatitis B-related liver cancer |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03003446A (en) | Novel medicinal herbal composition for treating liver diseases and hiv. | |
| CN101332284B (en) | Chinese traditional medicine composition for treating ulcerative colitis and its preparation method | |
| CN115634275A (en) | Traditional Chinese medicine preparation for treating liver cancer liver stagnation and spleen deficiency stasis toxin syndrome | |
| CN103550506A (en) | Traditional Chinese medicine composition cooperatively used in radiotherapy | |
| CN111407853B (en) | Traditional Chinese medicine composition for treating Parkinson's disease and preparation method thereof | |
| CN110339320B (en) | Traditional Chinese medicine composition for treating fatty liver | |
| CN112717081A (en) | Blood-activating face-beautifying cream formula and application thereof | |
| CN108379365B (en) | Medicine for preventing and treating diarrhea-predominant irritable bowel syndrome and preparation method and application thereof | |
| CN101020027A (en) | Medicine composition for preventing and treating AIDS and its prepn process and use | |
| CN107029173B (en) | Pharmaceutical composition for treating primary liver cancer | |
| CN115252753A (en) | Traditional Chinese medicine composition for treating insomnia and application thereof | |
| CN101461857B (en) | Medicament for treating severe hepatitis | |
| CN104042895A (en) | Traditional Chinese medicine composition for treating systemic lupus erythematosus and use thereof | |
| CN113713009A (en) | Traditional Chinese medicine composition for improving specific endowment constitution and preparation method and application thereof | |
| CN110613822A (en) | Anti-hepatitis B virus traditional Chinese medicine formula | |
| CN110732015A (en) | A Chinese medicinal composition for treating diabetes due to deficiency of both qi and yin | |
| CN114796417B (en) | Blood sugar reducing traditional Chinese medicine formula and preparation method thereof | |
| CN115581751B (en) | A Chinese medicinal composition for treating chronic hepatitis B, and its preparation method | |
| CN113952435B (en) | Traditional Chinese medicine composition for adjuvant treatment of liver cancer and preparation method thereof | |
| CN115998812B (en) | Traditional Chinese medicine composition for treating primary liver cancer and application thereof | |
| CN108567926B (en) | Traditional Chinese medicine composition for treating blood stasis collateral blocking type autoimmune hepatitis and preparation method thereof | |
| CN105395836A (en) | Application of traditional Chinese medicine composition to preparation of medicine for treating wind-warm lung-heat disease | |
| CN117771336A (en) | Traditional Chinese medicine composition for treating chronic hepatitis and preparation and application thereof | |
| CN115487264A (en) | Composition for reducing phlegm and removing stasis and preparation method thereof | |
| CN109925471A (en) | A kind of Chinese medicine composition for treating chronic hepatitis B and precancerous lesion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |